LianBio (LianBio) Debt-to-Equity : 0.01 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LianBio Debt-to-Equity?

LianBio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.89 Mil. LianBio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.95 Mil. LianBio's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $202.34 Mil. LianBio's debt to equity for the quarter that ended in Sep. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for LianBio's Debt-to-Equity or its related term are showing as below:

LIANY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.01 Max: 0.02
Current: 0.01

During the past 4 years, the highest Debt-to-Equity Ratio of LianBio was 0.02. The lowest was -0.03. And the median was 0.01.

LIANY's Debt-to-Equity is ranked better than
99.91% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs LIANY: 0.01

LianBio Debt-to-Equity Historical Data

The historical data trend for LianBio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LianBio Debt-to-Equity Chart

LianBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

-0.03

-0.01

0.01

0.02

LianBio Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial										0.02	0.02	0.02	0.02	0.01

Competitive Comparison of LianBio's Debt-to-Equity

For the Biotechnology subindustry, LianBio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LianBio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LianBio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where LianBio's Debt-to-Equity falls into.

LianBio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

LianBio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.851	+	2.488)	/	259.873
	=	0.02

LianBio's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.893	+	0.95)	/	202.338
	=	0.01

LianBio (OTCPK:LIANY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

LianBio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of LianBio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

LianBio (LianBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LianBio (OTCPK:LIANY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

103 Carnegie Center Drive, Suite 215, Princeton, NJ, USA, 08540

Website

https://www.lianbio.com

LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Wei Wei Chen	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON NJ 08540
Debra Yu	officer: See Remarks	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
C2 Life Sciences Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Lev Lb Holdings Gp, Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Venture Advisors, Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Brianne Jahn	officer: Chief Business Officer	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Yizhe Wang	director, officer: Chief Executive Officer	103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Jiang Qian	officer: China General Manager	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lev Lb Holdings, Lp	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Xontogeny Venture Fund, Lp	10 percent owner	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Yi Larson	officer: Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Neil Kumar	director	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304